The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.

Cardinal Health's Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, payable on July 15, 2026 to shareholders of record as of July 1, 2026. The dividend will be paid out of the company's capital surplus.

The Dow Jones surged 1.5% driven by industrial and healthcare stocks, while mega-cap tech faced pressure from concerns over AI capital spending. Meta and Microsoft declined on capex worries, but Alphabet gained on enterprise AI wins. Industrials like Caterpillar, Quanta Services, and Carrier rallied on data-center infrastructure demand. The S&P 500 gained 0.5% while the Nasdaq 100 remained flat.

Cardinal Health reported mixed Q3 2026 earnings with an EPS beat of $3.17 vs. $2.79 consensus, but revenue missed at $60.94B vs. $61.70B expected. Despite raising full-year guidance and reporting strong operational performance, the stock fell 8.23% to $186.12, likely due to the revenue miss and flat performance in the medical products segment.

The global radiopharmaceuticals market is projected to grow from USD 8.28 billion in 2026 to USD 15.21 billion by 2035, driven by rising cancer and cardiovascular disease incidence. North America dominates with 43.95% market share, while Asia-Pacific is expected to register the fastest growth. Therapeutic radiopharmaceuticals and Technetium-99m lead their respective segments, with hospitals and clinics as the primary end users.

The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.

The article examines three high-ROIC dividend-paying stocks: MasterCard, which reported strong Q4 2025 earnings with 17.3% revenue growth and 19% annual EPS growth; Starbucks, showing accelerating comparable store sales growth to 4% with expansion opportunities in China; and Cardinal Health, a major drug distributor posting 18.6% revenue growth and 39 consecutive years of dividend increases.

The global medical device cleaning market is projected to grow from USD 2.08 billion in 2024 to USD 3.74 billion by 2032, driven by escalating infection prevention requirements, expanding reusable device utilization, and technological advancements in automated reprocessing systems. However, high capital costs, complex regulatory obligations, and workforce training variability pose challenges to uniform adoption across regions.

Cardinal Health's Board of Directors approved a quarterly dividend of $0.5107 per share, payable on April 15, 2026 to shareholders of record as of April 1, 2026. The dividend will be paid from the company's capital surplus.

Cardinal Health (CAH) surged 9.11% to a new 52-week high after reporting strong Q2 results with adjusted EPS of $2.63 (beating consensus of $2.35) and sales of $65.63 billion (+19% YoY). The company raised its fiscal 2026 guidance for adjusted EPS to $10.15-$10.35 (+23% to +26% growth) and raised profit growth guidance across multiple segments.

Medline Industries, the largest IPO of 2025, is positioned as an attractive investment opportunity. The Chicago-based medical supply company has demonstrated strong historical growth with 18% average annual sales growth since 1966 and 50 consecutive years of net sales growth. With a $375 billion total addressable market and solid free cash flow projections, analysts expect continued momentum, though the stock trades at a lofty P/E multiple of 28.